SCHEMBL1689347

SCHEMBL1689347

NC(=O)C(C(=O)Nc1ccccc1)c1ccc(C(=O)Nc2nn(-c3ccccc3)cc2N)cc1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 10/20 0.55
HDAC2 Q92769 3/20 0.55
HDAC3 O15379 2/20 0.55
RAB9A P51151 1/20 0.44
ADORA3 P0DMS8 5/20 0.42
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
AURKA O14965 1/20 0.41
TP53 P04637 1/20 0.41
PARP1 P09874 1/20 0.40
NCOR2 Q9Y618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1754072 0.96 HDAC1 (0.60) HDAC1HDAC2HDAC3RAB9AADORA3
SCHEMBL1689405 0.92 HDAC1 (0.48) HDAC1HDAC2HDAC3RAB9AKDM4E
SCHEMBL13950308 0.88 HDAC1 (0.47) HDAC1HDAC2HDAC3RAB9AADORA3
SCHEMBL1689268 0.84 HDAC1 (0.44) HDAC1HDAC2HDAC3ADORA3KDM4E
SCHEMBL2107883 0.82 HDAC1 (0.62) HDAC1HDAC2HDAC3RAB9AADORA3
SCHEMBL2107532 0.82 HDAC1 (0.53) HDAC1HDAC2HDAC3RAB9AADORA3
SCHEMBL13985027 0.81 ADORA3 (0.51) HDAC1HDAC2ADORA3KDM4ELMNA
SCHEMBL2436869 0.80 CACNA1B (0.55) HDAC1HDAC2RAB9AADORA3KDM4E
SCHEMBL5135484 0.79 ADORA3 (0.49) HDAC1HDAC2ADORA3KDM4ELMNA
SCHEMBL2686355 0.78 HDAC1 (0.54) HDAC1RAB9AADORA3KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP claimed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US claimed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US claimed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP claimed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO claimed
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 HDAC1 6/4885HDAC2 42/4885HDAC3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.